Table 2

Primary efficacy endpoint results: ASAS20 response rate at week 12

Embedded Image

  • ***p≤0.001 versus placebo by normal approximation.

  • †Non-responder imputation was used: ASAS20 value was set to be non-responsive for patients who had no ASAS20 component data.

  • ASAS, Assessment of SpondyloArthritis International Society.